Allergan CEO Saunders hangs on to chairman's title, winning shareholder support — but not by a big enough margin to squelch critics
Brent Saunders will be hanging on to his chairman’s title for awhile longer.
The biopharma reported early Wednesday that 61.3% of its shares were cast …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
